

## General Genetic Testing, Somatic Disorders

Policy Number: AHS – M2146	Prior Policy Name and Number, as applicable: N/A
Initial Effective Date: June 1, 2023	Current Effective Date: June 1, 2023
Line(s) of Business: HMO; PPO; QUEST Integration; Medicare; FEP	Precertification: Required

### I. Policy Description

Genetic testing refers to the use of technologies that identify genetic variation, which include genomic, transcriptional, proteomic, and epigenetic alterations, for the prevention, diagnosis, and treatment of disease.

Somatic variations or mutations are defined as a genetic alteration that occurs after conception in any of the cells of the body, except the germ cells, and therefore are not passed on to offspring.

For guidance concerning Tumor Mutational Burden Testing (TMB) and/or Microsatellite instability (MSI) analysis please refer to the AHS-M2178-Microsatellite Instability and Tumor Mutational Burden Testing policy.

### II. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in Section VIII of this policy document.

*This policy addresses the general use of somatic (tumor) genetic testing and applies to all tests for which a policy addressing a specific clinical condition is not available.*

- 1) Genetic testing for a specific genetic mutation or mutations that have documented clinical utility **MEETS COVERAGE CRITERIA** for diagnosis, selection of therapy, or prognostication when there is a documented benefit based on the presence of such mutations in the tumor, or neoplastic cells.
- 2) Repeat testing **MEETS COVERAGE CRITERIA** for recurrence monitoring, OR
- 3) Repeat testing **MEETS COVERAGE CRITERIA** when there is the possibility of further genetic alterations in the hematologic malignancy, primary tumor or metastasis AND knowledge of these changes would result in the addition, elimination, or alteration of non-investigational therapies.

*The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of a patient's illness.*

- 4) Testing with a gene panel containing genes that do not meet the criteria in item 1 above **DOES NOT MEET COVERAGE CRITERIA**.

Note: For 5 or more gene tests being run on a tumor specimen (i.e., non-liquid biopsy) on the same platform, such as multi-gene panel next generation sequencing, please refer to AHS-R2162

## Reimbursement Policy.

### III. Table of Terminology

Term	Definition
ACMG	American College of Medical Genetics and Genomics
ACTC1	<i>Actin alpha cardiac muscle 1</i>
AMP	Association For Molecular Pathology
APC	<i>Adenomatous polyposis coli</i>
APOB	<i>Apolipoprotein B</i>
ASCO	American Society of Clinical Oncology
ATP7B	<i>ATPase copper transporting beta</i>
BMPR1A	<i>Bone morphogenetic protein receptor type 1A</i>
BRCA	<i>Breast cancer gene</i>
BRCA1	<i>Breast cancer gene 1</i>
BRCA2	<i>Breast cancer gene 2</i>
BSG	British Sarcoma Group
CACNA1S	<i>Calcium voltage-gated channel subunit alpha1 S</i>
CAP	College Of American Pathologists
CD	<i>Cluster of differentiation</i>
CD34	<i>Cluster of differentiation 34</i>
CGP	Comprehensive genomic profiling
CLIA '88	Clinical Laboratory Improvement Amendments Of 1988
CMS	Centers For Medicare and Medicaid
CNAs	Copy number alterations
CNV	Copy number variant
COL3A1	<i>Collagen type III alpha 1</i>
CTLA-4	<i>Cytotoxic T-lymphocyte-associated protein 4</i>
D842V	<i>Platelet derived growth factor receptor alpha</i>
dMMR	Mismatch repair deficiency
DNA	Deoxyribonucleic acid
DOG1	Delay of germination
DSC2	<i>Desmocollin-2</i>
DSG2	<i>Desmoglein 2</i>
DSP	<i>Desmoplakin</i>
EGISTs	Extragastrintestinal stromal tumors
EP	Expected pathogenic
ESCAT	ESMO Scale for Clinical Actionability of molecular Targets
ESMO	European Society for Medical Oncology
EZH2	<i>Enhancer of zeste 2 polycomb repressive complex 2 subunit</i>
FBN1	<i>Fibrillin-1</i>
FDA	Food and Drug Administration
FFPE	Formalin-fixed paraffin embedded
FISH	Fluorescence in situ hybridization
GIS	Genomic instability score
GISTs	Gastrointestinal stromal tumors

GLA	<i>Alpha-galactosidase A</i>
GRASP	Genome-Wide Repository of Associations Between SNPs And Phenotypes
HGSC	High-grade serous ovarian, fallopian tube, and peritoneal carcinoma
HOXC6	<i>Homeobox C6</i>
HRD	Homologous recombination deficiency
HRR	Homologous recombination repair
Indel	Insertion/deletion
KCNH2	<i>Potassium voltage-gated channel subfamily H member 2</i>
KCNQ1	<i>Potassium voltage-gated channel subfamily Q member 1</i>
KIT	<i>KIT proto-oncogene receptor tyrosine kinase</i>
LP	Likely pathogenic
LDLR	Low density lipoprotein receptor
LDTs	Laboratory-developed tests
LMNA	Lamin A/C
LOF	Loss of function
LOH	Loss of heterozygosity
LST	Large scale state transitions
MBR	Major breakpoint region
MCR	Minor cluster region
MLH1	<i>MutL homolog 1</i>
MSH2	<i>MutS homolog 2</i>
MSH6	<i>MutS homolog 6</i>
MSI	Microsatellite instability
MSK-IMPACT	Memorial Sloan Kettering- integrated mutation profiling of actionable cancer targets
MUTYH	<i>MutY DNA glycosylase</i>
MYBPC3	<i>Myosin binding protein C</i>
MYH7	<i>myosin heavy chain 7</i>
MYH11	<i>myosin heavy chain 11</i>
MYL2	<i>Myosin light chain 2</i>
MYL3	<i>Myosin light chain 3</i>
NCCN	National Comprehensive Cancer Network
NF2	<i>Neurofibromin 2</i>
NGS	Next generation sequencing
NSCLC	Non-small cell lung cancer
OCEANs	Oncogene Concatenated Enriched Amplicon Nanopore Sequencing
ORR	Overall response rate
OTC	<i>Ornithine transcarbamylase</i>
PARPi	Poly-ADP ribose inhibitors
PCR	Polymerase chain reaction
PCSK9	<i>Proprotein convertase subtilisin/kexin type 9</i>
PD-1/PD-L1	<i>Programmed death-1/ programmed death ligand-1</i>
PDGFRA	<i>Platelet-derived growth factor receptor alpha</i>
PKP2	<i>Plakophilin 2</i>
PMS2	<i>PMS1 homolog 2, mismatch repair system component</i>
poly-ADP	Polymeric adenosine diphosphate

<i>PRKAG2</i>	<i>Protein kinase AMP-activated non-catalytic subunit gamma 2</i>
<i>PTEN</i>	<i>Phosphatase and tensin homolog</i>
<i>RB1</i>	<i>RB transcriptional corepressor 1</i>
RNA	Ribonucleic acid
<i>RYR1</i>	<i>Ryanodine receptor 1</i>
<i>RYR2</i>	<i>Ryanodine receptor 2</i>
SCL	Small-cell lung cancer
<i>SCN5A</i>	<i>Sodium voltage-gated channel alpha subunit 5</i>
SCNEC	Small cell neuroendocrine carcinoma
<i>SDHAF2</i>	<i>Succinate dehydrogenase complex assembly factor 2</i>
<i>SDHB</i>	<i>Succinate dehydrogenase complex subunit B</i>
<i>SDHC</i>	<i>Succinate dehydrogenase complex subunit C</i>
<i>SDHD</i>	<i>Succinate dehydrogenase cytochrome b</i>
<i>SMAD4</i>	<i>Mothers against decapentaplegic homolog 4</i>
SNPs	Single nucleotide polymorphisms
<i>STK11</i>	<i>Serine/threonine kinase 11</i>
STR	Short tandem repeat
TAI	Telomeric allelic imbalance
TF	Tumor fraction
<i>TGFBR1</i>	<i>Transforming growth factor, beta receptor I</i>
<i>TGFBR2</i>	<i>Transforming growth factor, beta receptor II</i>
TMB	Tumor mutational burden
<i>TMEM43</i>	<i>Transmembrane protein 43</i>
<i>TP53</i>	<i>Tumor protein P53</i>
<i>TSC1</i>	<i>Tuberous sclerosis complex 1</i>
<i>TSC2</i>	<i>Tuberous sclerosis complex 2</i>
UPD	Uniparental disomy
VUS	Variants of unknown significance
WES	Whole-exome sequencing
<i>WT1</i>	<i>Wilms' tumor 1</i>

#### IV. Scientific Background

Gene mutations are referred to as “somatic” if they are not within the germline (i.e., within gametes); therefore, these mutations are not passed on from parent to offspring. Somatic mutations may arise *de novo* or later in life and are very common in neoplasms. There are many different types of somatic mutations, including single nucleotide polymorphisms (SNPs); structural variations such as deletions, inversions, or translocations, and smaller chromosomal abnormalities such as short tandem repeats or gene fusions. Most mutations do not result in disease.

SNPs are the most common type of genetic mutation, including missense mutations. These mutations are single base-pair changes where one nucleotide replaces a different nucleotide. More than 65% of the diseases caused by genetic mutations are due to SNPs. Estimates based on whole genome sequencing have placed the average amount of SNPs in any given individual at 2.8 to 3.9 million. Insertion/deletion (indel) polymorphisms are often a single nucleotide but may be up to four nucleotides. SNPs often lead to frameshift mutations that can cause premature stop codons and the failure of the allele.

Structural variations are usually classified as larger than 1000 base pairs. These include deletions, duplications, inversions, translocations, or ring chromosome formations. Due to the large number of genes affected, these variations commonly lead to severe genetic abnormalities; for example, a major cause of chronic myeloid leukemia is due to the translocation between chromosomes 9 and 22, resulting in a fused gene. The most common structural variation is the copy number variant (CNV), referring to a differing number of DNA segment copies in different individuals. For example, one person may have three copies of a particular segment whereas another may only have two. These variations may lead to dysregulation, gain-of-function, or loss-of-function of the affected genes. The sensitive genes that require or produce precise quantities of a protein product tend to suffer more from these variations.

Any size mutation may be pathogenic and must be categorized as to how likely the mutation is to cause disease. The American College of Medical Genetics and Genomics (ACMG) has classified mutations in five categories, which are as follows: pathogenic, likely pathogenic, uncertain significance, likely benign, and benign. The “likely pathogenic” and “likely benign” refer to weaker evidence than their respective pathogenic and benign categories, and “uncertain significance” refers to evidence that does not meet criteria for benignity or pathogenicity or has conflicting evidence from both sides. Prediction algorithms have been used to interpret variants and to predict whether a variant will affect the gene function or splicing of the gene. These algorithms are publicly available but have a tendency of predicting the harmful impact of a variant. The specificity of these databases has been estimated at 60-80%.

Due to the enormous number of variants, as well as the rate that variants are discovered, comprehensive databases of genetic variants have been published and are easily available. For example, the Genome-Wide Repository of Associations Between SNPs and Phenotypes (GRASP) database includes information from over 2000 studies and over one million variant-related results. Databases focusing on cancer-specific variants, reference sequences, and the general population are all available publicly.

Spontaneous mutations accumulate in somatic cells over a lifetime. Early somatic mutations can cause developmental disorders while the accumulation of mutations throughout life can lead to cancer and contribute to aging. Molecular profiles of tumors have clinical utility in guiding the clinical management of cancer patients, providing diagnostic or prognostic information, or identifying a potential treatment regimen. Increasingly, somatic mutations are being identified in diseases other than cancer, such as neurodevelopmental diseases.

A malignant neoplasm is another term for cancer, which may encompass many types including breast, prostate, skin, lung, rectum, colon, and brain. Gastrointestinal stromal tumors (GISTs) are considered rare neoplasms with approximately 95% of these cancers non-hereditary; GISTs are mainly identified by KIT protein expression with typical mutations in the *KIT* or platelet-derived growth factor receptor alpha (*PDGFRA*) genes. These GISTs are the most common mesenchymal tumor of the gastrointestinal tract that originate from the cell of Cajal. Primary prostate and lung tumors have been associated with different types of GISTs such as gastric and small bowel; genetic analysis of one patient found “that the gastric GIST and abdominal tumors were characterized by two different c-KIT mutations (Comandini et al., 2017).” Extra-gastrointestinal stromal tumors (EGISTs) are another type of rare neoplasm which also arise in the gastrointestinal tract. Liu et al. (2014) report that an EGIST was identified in the prostate of a male patient. “The results of immunohistochemical staining showed positive immunoreactivity for cluster of differentiation (CD)117 (c-kit), CD34 and DOG1 in the tumor. On mutation analysis, loss of heterozygosity of the c-kit gene was observed in the prostatic EGIST; however, the

platelet-derived growth factor receptor- $\alpha$  (*PDGFRA*) gene was normal.” Due to the rarity of EGIST of the prostate, immunohistochemistry analysis is important to confirm a diagnosis.

Mutations of the *KIT* and *PDGFRA* genes in small cell neuroendocrine carcinoma (SCNEC) of the prostate have been researched by Terada (2012). A total of 706 malignant prostate tumors were identified, and four of these tumors were classified as SCNEC. Of these four tumors, three tumors were positive for *KIT*, and *PDGFRA*, among other genes. Molecular genotyping via PCR showed no *KIT* or *PDGFRA* mutations. Another study completed by McCabe et al. (2008) noted that homeobox C6 (*HOXC6*) is overexpressed in prostate cancers and completed an analysis of prostate cancer cells to identify which promoters are bound by *HOXC6*. “We show that *HOXC6* directly regulates expression of bone morphogenic protein 7, fibroblast growth factor receptor 2, insulin-like growth factor binding protein 3, and platelet-derived growth factor receptor alpha (*PDGFRA*) in prostate cells.” The researchers also note that *PDGFRA* is able to reduce the proliferation of prostate cancer cells, and that if *HOXC6* is overexpressed, the effects of *PDGFRA* inhibition may be overcome. The fusion gene *FIP1L1-PDGFRA* has also been associated with chronic eosinophilic leukemia.

### **Proprietary Testing**

Clinical biomarkers are widely used for making personalized and actionable decisions for cancer treatment. Tumor mutational burden (TMB), the number of somatic mutations per mega base of the DNA in cancer cells, is an emerging biomarker associated with predicting the response to immunotherapy treatment. A high TMB value indicates better treatment outcomes, which is observed in patients with melanoma on CTLA-4 inhibitors and patients with melanoma, non-small-cell lung carcinoma, bladder cancer, microsatellite instability cancers, and pan-tumors on PD-1/PD-L1 inhibitors. High TMB has also been associated with improved outcomes in patients on a combination of PD-1/PD-L1 and CTLA-4 inhibitors (Merino et al., 2020). TMB was originally measured with whole-exome sequencing (WES), but this method has limited clinical utility due to a 6–8-week sequencing period and expensive costs. Alternatively, targeted NGS panels can reliably estimate TMB from a subset of the exome with reduced sequencing time and increased clinical application. 2 FDA-approved products for calculating TMB include the FoundationOne CDx assay (Foundation Medicine Inc.) and MSK-IMPACT (Memorial Sloan Kettering Cancer Center). Both of these tests, referred to as comprehensive genomic profiling (CGP), can identify all types of “molecular alterations (i.e., single nucleotide variants, small and large insertion-deletion alterations, copy number alterations, and structural variants) in cancer-related genes, as well as genomic signatures such as microsatellite instability (MSI), loss of heterozygosity, and TMB (Klempner et al., 2020).” Studies show that TMB calculation from CGP has high concordance with TMB measured from WES. On June 16, 2020, the FDA approved pembrolizumab for the treatment of adult and pediatric patients with a TMB value of greater than 10 mutations per mega base as determined by the FoundationOne CDx assay.

Analysis of somatic mutations in solid tumors and hematologic malignancies using next-generation sequencing has become common practice in oncology clinics as well as clinical trials. There are 2 known approved NGS tests for detection of somatic mutations. MyChoice HRD CDx, by Myriad Genetic Laboratories, was FDA-approved on October 23, 2019, and ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) by Pillar Biosciences was FDA-approved on July 30, 2021. Myriad MyChoice® CDx is a next generation sequencing-based in vitro diagnostic test that detects single nucleotide variants, insertions and deletions, and large rearrangement variants in protein coding regions and intron/exon boundaries of



the *BRCA1* and *BRCA2* genes. The ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) by Pillar Biosciences, is a next generation sequencing test for detection of somatic mutations for non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) tumor tissue. The test simultaneously detects clinically relevant mutations in *KRAS* for CRC and *EGFR* for NSCLC in a single assay. In the accuracy study, positive percent agreement (PPA) and negative percent agreement (NPA) between O/RDx-LCCA and externally validated comparator method (CompO) was >99%. The authors conclude that O/RDx-LCCA "is a highly accurate assay for the detection of clinically relevant *KRAS* variants in CRC and *EGFR* variants in NSCLC."

In 2020, the FDA approved Guardant360® CDx for tumor mutation profiling in patients with any solid malignant neoplasm. The Guardant360 CDx is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor (*EGFR*) alterations who may benefit from treatment with Tagrisso® (osimertinib) (Guardant, 2020). In an analytical study, the positive and negative percent agreement for Guardant360 CDx relative to Therascreen® *KRAS* RGQ PCR was 0.71 and 1.00 respectively; overall percent agreement was 0.82 (Bauml et al., 2021). In 2020, the FDA also approved Therascreen BRAF V600E RGQ PCR Kit by QIAGEN. This is a real-time PCR test for the qualitative detection of V600E mutations in the *BRAF* gene in human colorectal cancer (CRC) tumor tissue. Therascreen can help select patients with metastatic colorectal cancer (mCRC) whose tumors carry the *BRAF* V600E mutation for treatment with BRAF TOVI (encorafenib) in combination with cetuximab.

### **Analytical Validity**

Woodhouse et al. (2020) evaluated the analytical performance of FoundationOne Liquid CDx assay to detect genomic alterations in cancer patients. The assay was evaluated across more than 30 different cancer types in over 300 genes and greater than 30,000 gene variants. "Results demonstrated a 95% limit of detection of 0.40% variant allele fraction for select substitutions and insertions/deletions, 0.37% variant allele fraction for select rearrangements, 21.7% tumor fraction (TF) for copy number amplifications, and 30.4% TF for copy number losses. The false positive variant rate was 0.013% (approximately 1 in 8,000). Reproducibility of variant calling was 99.59%." In comparison to in situ hybridization and immunohistochemistry, FoundationOne had an overall 96.3% positive percent agreement and > 99.9% negative percent agreement. "These study results demonstrate that FoundationOne Liquid CDx accurately and reproducibly detects the major types of genomic alterations in addition to complex biomarkers such as microsatellite instability, blood tumor mutational burden, and tumor fraction."

Thirunavukarasu developed the Oncogene Concatenated Enriched Amplicon Nanopore Sequencing (OCEANS) method for rapid, accurate, and affordable somatic mutation detection. The OCEANS method involves amplified variants with low variant allele frequency (VAFs) and subsequently concatenating with Nanopore Sequencing. In this study, the 15-plex OCEANS melanoma panel was compared to NGS. OCEANS had a 100% sensitivity relative to NGS. Of the 9584 NGS-negative loci, OCEANS was able to detect an additional 97 variants; thus, relative to NGS, OCEANS had a 99.0% specificity and very low false positive rate. These 97 NGS-negative and OCEANS-positive results were believed to be true mutations, and droplet digital PCR (ddPCR) confirmation experiments supported this hypothesis. The authors conclude that "Integrating OCEANS with long-read and base modification detection capabilities of Nanopore Sequencing can enable development of comprehensive oncology panels."

### **Clinical Validity and Utility**

Advancements in technology and availability of sequencing, previously constrained by limitations of sequential single-gene testing on limited patient samples, have led to significant strides in our understanding of the genetic basis of inherited and somatic conditions. Variants detected by genetic testing include inherited germline variants and somatic mutations; next generation sequencing (NGS) has allowed for superior detection of these mutations. The accuracy of NGS varies depending on how many genes are sequenced; fewer genes tend to result in higher accuracy since there will be more “probe-template overlap.” Although Sanger sequencing remains the most accurate at >99.99% accuracy, it cannot sequence a large number of genes in a timely fashion and is best used for sequencing of a specific gene.

NGS has been used to identify several types of somatic mutations associated with cancer and may help to single out therapeutic targets. Genetic mutations in *BRCA1* & 2 are associated with breast and ovarian cancer. Kowalik et al. (2019) have identified somatic genetic mutations in *BRCA1* & 2 for ovarian cancer prognostic purposes using NGS. Ovarian cancer tissue samples were used for the analysis. A total of 3% of mutations (6/201) were identified as somatic; with only 24% (49/201) of samples identified with a pathogenic mutation overall. The other 35 mutations were of germline origin. This corroborated the report by Nagahashi et al. (2019) which states that approximately 2.5% of *BRCA1* & 2 mutations are somatic.

The clinical validity of a genetic test depends primarily on the expressivity and penetrance of a given phenotype. Penetrance refers to the likelihood of developing a disease when the pathogenic mutation is present, and expressivity refers to the variations in the way the disease is expressed. For example, virtually any mutation in the *APC* gene will cause symptoms of familial adenomatous polyposis, thereby increasing the clinical validity of an *APC* assessment. Some conditions may not clinically manifest at all despite a mutated genotype.

The clinical utility of a genetic test generally relies on available treatments for a condition. Conditions such as Huntington’s Disease that do not have many options for treatment will have limited clinical utility compared to another condition even though the actual test is highly valid. Factors such as severity of the disease and management options affect the clinical utility of a genetic test.

Hayano et al. (2016); McCabe et al. (2008) noted that homeobox C6 (*HOXC6*) is overexpressed in prostate cancers and completed an analysis of prostate cancer cells to identify which promoters are bound by *HOXC6*.

In a multi-cohort, open-label, non-randomized study to establish the relationship between TMB and pembrolizumab treatment response, 790 patients were tested for TMB with the FoundationOne CDx assay. 102/790 patients had high TMB ( $\geq 10$  mutations per mega base) in solid tumors of anal, biliary, cervical, endometrial, mesothelioma, neuroendocrine, salivary, small cell lung, thyroid, and vulvar cancers. The overall response rate (ORR) in patients with a high TMB was 29%, with a 4% complete response rate and 25% partial response rate compared to an ORR of 6% in patients with a low TMB. The overall response rate was nearly 5-fold in patients with a high TMB. The authors conclude “TMB could be a novel and useful predictive biomarker for response to pembrolizumab monotherapy in patients with previously treated recurrent or metastatic advanced solid tumours.”

In a prospective study, Takeda evaluated the clinical application of the FoundationOne CDx Assay in decision-making for patients with advanced solid tumors. 175 samples were analyzed using the



FoundationOne assay and 153 of these patients were assessed for TMB. "The most commonly known or likely pathogenic variants were *TP53* mutations (n = 113), *PIK3CA* mutations (n = 33), *APC* mutations (n = 32), and *KRAS* mutations (n = 29). The median TMB was 4 mutations/Mb, and tumors with a high TMB ( $\geq 10$  mutations/Mb) were more prevalent for lung cancer (11/32) than for other solid tumor types." From the 175 samples found to have known or likely pathogenic variants, 24 subjects (14%) received the optimal targeted therapy. The authors conclude that "such testing may inform the matching of patients with cancer with investigational or approved targeted drugs."

## V. Guidelines and Recommendations

### **Association for Molecular Pathology (AMP), American Society of Clinical Oncology (ASCO), and College of American Pathologists (CAP)**

The Joint Commission recommended that somatic variants be categorized by and reported based on their impact on clinical care. The Joint Commission notes that somatic variants include indels, SNVs, fusion genes from genomic rearrangements, and CNVs and should focus on their impact on clinical care. Any variant may be considered a biomarker if it predicts response to therapy, influences prognosis, diagnosis, treatment decisions, or the gene function itself. The Joint Commission proposes four levels for these biomarkers which are as follows:

- "1. Level A, biomarkers that predict response or resistance to US FDA-approved therapies for a specific type of tumor or have been included in professional guidelines as therapeutic, diagnostic, and/or prognostic biomarkers for specific types of tumors;
2. Level B, biomarkers that predict response or resistance to a therapy based on well-powered studies with consensus from experts in the field, or have diagnostic and/or prognostic significance of certain diseases based on well-powered studies with expert consensus;
3. Level C, biomarkers that predict response or resistance to therapies approved by FDA or professional societies for a different tumor type (i.e., off-label use of a drug), serve as inclusion criteria for clinical trials, or have diagnostic and/or prognostic significance based on the results of multiple small studies;
4. Level D, biomarkers that show plausible therapeutic significance based on preclinical studies, or may assist disease diagnosis and/or prognosis themselves or along with other biomarkers based on small studies or multiple case reports with no consensus."

The Joint Commission also includes variants in different tiers based on the amount of evidence there is to support its significance. For example, tier 1 variants include significance of levels A and B, while tier 2 includes significance of levels C and D. Tier 3 is variants of unknown significance (VUS), such as variants in cancer genes that have not been reported in any other cancers. These variants are not typically seen in significant frequencies in the general population. When evaluating these variants, the type of mutation and gene function should be considered. Tier 4 is benign variants or likely benign variants. These alleles are often observed in significant amounts in general populations. Tier 3 variants should be reported while ensuring that the most important information is communicated to the patient.

### **National Comprehensive Cancer Network (NCCN)**

Multiple somatic mutations have been incorporated into the diagnostic workups recommended by the

NCCN. Furthermore, the NCCN has several guidelines which recommend that gene expression profiling, or multiple gene testing, may be helpful, more efficient and/or cost-effective for selected patients. Please see the individual policies.

### American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP)

The ACMG and AMP released criteria on the types and severity of mutations, which are as follows:

- **Very strong evidence of pathogenicity:** Null variants (nonsense, frameshifts, canonical +/- 1-2 splice sites, initiation codon, exon deletions) in a gene where loss of function (LOF) is a known mechanism of disease. The guidelines note to use caution in genes where LOF is not a mechanism, if LOF variants are at the 3' end, if exon skipping occurs, and if multiple transcripts are present.
- **Strong:** Amino acid change to a pathogenic version, de novo mutations, established studies supporting a damaging gene or gene product, or if the prevalence of the variant is increased in affected individuals compared to healthy controls. The guidelines note to be careful of changes impacting splicing and if only the paternity has been confirmed.
- **Moderate:** Located in a mutational hot spot or well-established functional domain (e.g., active site of an enzyme) without a benign variation, absent from controls in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium, detected in *trans* with pathogenic variants for a recessive disorder, protein length changes, novel missense changes where a different missense change has been pathogenic before, and a possible de novo mutation.
- **Supporting:** Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease, missense variant in a gene with low rate of benign missense variation, if the mutation has evidence that it is deleterious, if the patient's phenotype is highly specific for disease with a single genetic cause.

The guidelines also list criteria for benign gene variants.

- **Stand-alone evidence of benignity:** Allele frequency is >5% in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium
- **Strong:** Allele frequency is greater than expected for disorder, observed in healthy adult with full penetrance at early age, lack of segregation in affected family members (although pathogenic variants may masquerade as nonsegregated), or well-established studies that show no damaging effect on protein production.
- **Supporting:** Missense variant of a gene for which truncating mutations are pathogenic, indels in repetitive region of unknown function, silent variants, variants of unknown significance, or a *trans* version of a *cis* mutation.

### American College of Medical Genetics and Genomics (ACMG)

The ACMG has released a list of genes for which secondary findings should be disclosed. Secondary findings refer to incidental findings unrelated to why a genetic test was originally ordered but are of significant clinical value to the patient. The portion of the table containing the conditions, the associated genes, and which variants should be report is listed below:

Condition	Gene(s)	Variants to
-----------	---------	-------------

		Report
Breast/ovarian cancer	<i>BRCA1, BRCA2</i>	LP (likely pathogenic), P (pathogenic)
Li-Fraumeni syndrome	<i>TP53</i>	LP, P
Peutz-Jeghers syndrome	<i>STK11</i>	LP, P
Juvenile polyposis syndrome	<i>BMPR1A, SMAD4</i>	LP, P
PTEN hamartoma syndrome	<i>PTEN</i>	LP, P
Lynch syndrome	<i>MLH1, MSH2, MSH6, PMS2,</i>	LP, P
Familial adenomatous polyposis	<i>APC</i>	LP, P
MYH-associated polyposis	<i>MUTYH</i>	LP, P
Von Hippel Lindau syndrome	<i>VHL</i>	LP, P
Retinoblastoma	<i>RB1</i>	LP, P
Tuberous sclerosis complex	<i>TSC1, TSC2</i>	LP, P
Wilms tumor	<i>WT1</i>	LP, P
Multiple endocrine neoplasia 1 or 2	<i>MEN1 (1), RET (2)</i>	LP, P
Familial medullary thyroid cancer	<i>RET</i>	LP, P
Hereditary paraganglionoma-pheochromocytoma syndrome	<i>SDHD, SDHAF2, SDHC, SDHB</i>	LP, P
Neurofibromatosis type 2	<i>NF2</i>	LP, P
Marfan syndrome, Loeys-Dietz syndrome, familial thoracic aortic aneurysms and dissections	<i>FBN1, TGFB1, TGFB2, SMAD3, ACTA2, MYH11</i>	LP, P
Malignant hyperthermia	<i>RYR1, CACNA1S</i>	LP, P
Wilson disease (copper metabolism)	<i>ATP7B</i>	LP, P
Ornithine transcarbamylase deficiency (urea cycle)	<i>OTC</i>	All hemi, het, homozygous P and LP
Hereditary hemochromatosis	<i>HFE</i>	HFE p.Cys282Tyr homozygotes only
Hereditary hemorrhagic telangiectasia	<i>ACVRL1, ENG</i>	LP, P
Maturity-onset diabetes of the young	<i>HNF1A</i>	LP, P

<b>RPE65-related retinopathy</b>	<i>RPE65</i>	LP, P
----------------------------------	--------------	-------

<b>Cardiac and/or blood vessel related</b>		
<b>Condition</b>	<b>Gene(s)</b>	<b>Variants to Report</b>
<b>Aortopathies</b>	<i>FBN1, TGFB1, TGFB2, SMAD3, ACTA2, MYH11</i>	LP, P
<b>Arrhythmogenic right ventricular cardiomyopathy</b>	<i>PKP2, DSP, DSC2, TMEM43, DSG2</i>	LP, P
<b>Catecholaminergic polymorphic ventricular tachycardia</b>	<i>RYR2, CASQ2, TRDN</i>	LP, P
<b>Dilated cardiomyopathy</b>	<i>TNNT2, LMNA, FLNC, TTN</i>	LP, P
<b>Ehlers–Danlos syndrome, vascular type</b>	<i>COL3A1</i>	LP, P
<b>Familial hypercholesterolemia</b>	<i>LDLR, APOB, PCSK9</i>	LP, P
<b>Hypertrophic cardiomyopathy</b>	<i>MYH7, MYBPC3, TNNI3, TPM1, MYL3, ACTC1, PRKAG2, MYL2</i>	LP, P
<b>Long QT syndrome types 1 and 2</b>	<i>KCNQ1, KCNH2</i>	LP, P
<b>Long QT syndrome 3; Brugada syndrome</b>	<i>SCN5A</i>	LP, P
<b>Genes related to inborn errors of metabolism phenotypes</b>		
<b>Condition</b>	<b>Gene(s)</b>	<b>LP, P</b>
<b>Biotinidase deficiency</b>	<i>BTBD</i>	LP, P (2 variants)
<b>Fabry disease</b>	<i>GLA</i>	All hemi, het, homozygous P and LP
<b>Ornithine transcarbamylase deficiency</b>	<i>OTC</i>	All hemi, het, homozygous P and LP
<b>Pompe disease</b>	<i>GAA</i>	P and LP (2 variants)

## American Society of Clinical Oncology (ASCO)

The ASCO published guidelines regarding genetic and genomic testing for cancer susceptibility. These guidelines state that the “ASCO recognizes that concurrent multigene testing (i.e., panel testing) may be efficient in circumstances that require evaluation of multiple high-penetrance genes of established clinical utility as possible explanations for a patient’s personal or family history of cancer. Depending on the specific genes included on the panel employed, panel testing may also identify mutations in genes associated with moderate or low cancer risks and mutations in high-penetrance genes that would not have been evaluated on the basis of the presenting personal or family history... ASCO affirms that it is sufficient for cancer risk assessment to evaluate genes of established clinical utility that are suggested by the patient’s personal and/or family history.”

ASCO released guidelines regarding somatic tumor testing for ovarian cancer. ASCO recommends that “Women diagnosed with clear cell, endometrioid, or mucinous ovarian cancer should be offered somatic tumor testing for mismatch repair deficiency (dMMR). Somatic tumor testing for *BRCA1* and *BRCA2* pathogenic or likely pathogenic variants may be reserved for time of recurrence for women who have completed upfront therapy and are currently in observation, as presence of these mutations qualifies the patient for FDA-approved treatments.” In a 2021 update of these guidelines, ASCO adds “Implementation of techniques and pipelines enabling both SNV and CNV detection should be preferred, optimally by next-generation sequencing.”

#### **European Society for Medical Oncology (ESMO)**

The ESMO recommends that “Mutational analysis inclusion in the diagnostic work-up of all GISTs should be considered standard practice [II, A] (with the possible exclusion of < 2 cm non-rectal GISTs).” The article also states that “Mutational analysis for known mutations involving *KIT* and *PDGFRA* can confirm the diagnosis of GIST, if doubtful (particularly in rare CD117/DOG1-negative suspect GIST). Mutational analysis has a predictive value for sensitivity to molecular-targeted therapy and to prognostic value. Its inclusion in the diagnostic work-up of all GISTs should be considered standard practice.”

The ESMO Translational Research and Precision Medicine Working Group released clinical practice guidelines to define best practice for homologous recombination deficiency (HRD) testing in high-grade serous ovarian, fallopian tube and peritoneal carcinoma (HGSC). ESMO recommends that “pathological evaluation of the tumour tissue specimens used for assessment of somatic molecular alterations is essential.” Regarding homologous recombination repair (HRR) tests, *BRCA* germline and somatic mutation tests are recommended as they consistently identify the subgroup of ovarian cancer patients who benefit the most from poly-ADP ribose inhibitors (PARPi) therapy. There is insufficient evidence to determine the clinical validity of a panel of non-*BRCA* HRR genes and *BRCA1* or *RAD51C* promoter methylation to predict PARPi benefit. “In the first-line maintenance setting, germline and somatic *BRCA* mutation testing is routinely recommended to identify HGSC patients who should receive a PARPi.”

#### **British Sarcoma Group (BSG)**

The BSG has published guidelines on the management of GIST and state that most GIST cases are associated with a *KIT* or *PDGFRA* mutation. The guidelines recommend the following:

- “The diagnosis should be made by a pathologist experienced in the disease and include the use of immunohistochemistry and mutational analysis, which should be performed by an accredited laboratory.
- If neoadjuvant treatment with imatinib is planned, it is vital to confirm the diagnosis, since there is

a wide differential. It may be necessary to perform a percutaneous core needle biopsy if the tumour is inaccessible to endoscopic ultrasound-guided biopsy. Mutational analysis is obligatory, since some GISTs are insensitive to imatinib (e.g. those with *D842V* mutation in exon 18 of *PDGFRA*)."

**European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Geriatric Oncology (SIOG)**

EAU/EANM/ESTRO/ESUR/SIOG released guidelines on prostate cancer in 2021. These guidelines strongly recommend offering patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) "somatic molecular testing to identify patients suitable for treatment with PARP inhibitors."

**The American Urological Association / American Society for Radiation. Oncology / Society of Urologic Oncology (AUA/ASTRO/SUO)**

AUA/ASTRO/SUO released guidelines on prostate cancer in 2021. These guidelines recommend that "clinicians should offer germline and somatic tumor genetic testing to identify DNA repair deficiency mutations and microsatellite instability status that may inform prognosis in patients with mCRPC and counseling regarding family risk as well as potential targeted therapies."

## VI. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

### Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

On July 30, 2021, the FDA approved ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) by Pillar Biosciences. "The device is a qualitative next generation sequencing based in vitro diagnostic test that uses amplicon-based target enrichment technology for detection of single nucleotide variants (SNVs) and deletions in 2 genes from DNA isolated from formalin-fixed paraffin-embedded (FFPE) non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) tumor tissue specimens."

On July 18, 2020, the FDA approved Cobas® EZH2 Mutation Test, a somatic gene mutation detection system by Roche Molecular System, Inc. "The device is a real-time allele-specific PCR test for qualitative detection of single nucleotide mutations for *Y646N*, *Y646F* or *Y646X* (*Y646H*, *Y646S*, or *Y646C*), *A682G*, and *A692V* of the *EZH2* gene in DNA extracted from formalin fixed paraffin embedded (FFPE) human follicular lymphoma tumor tissue specimens."



On August 7, 2020, the FDA approved Guardant360 CDx, by Guardant Health, Inc. This device is a next generation sequencing based in vitro diagnostic device that uses targeted high throughput hybridization-based capture technology to detect SNVs, insertions, and deletions in 55 genes, copy number amplifications in 2 genes, and fusions in 4 genes. Guardant360 CDx also utilizes circulating cell-free DNA collected in Streck Cell-Free DNA Blood Collection Tubes to identify non-small cell lung cancer (NSCLC) patients who may benefit from treatment with the targeted therapy.

On April 15, 2020, the FDA approved Therascreen *BRAF* V600E RGQ PCR Kit by QIAGEN. The Therascreen *BRAF* V600E RGQ PCR Kit is a real-time PCR test for the qualitative detection of V600E mutations in the *BRAF* gene using genomic DNA extracted from formalin-fixed paraffin-embedded (FFPE) human colorectal cancer (CRC) tumor tissue. The Therascreen *BRAF* V600E RGQ PCR Kit is an in vitro diagnostic device intended to be used as an aid in selecting patients with metastatic colorectal cancer (mCRC) whose tumors carry the *BRAF* V600E mutation for treatment with BRAFTOVI (encorafenib) in combination with cetuximab.”

On October 23, 2019, the FDA approved MyChoice HRD CDx, by Myriad Genetic Laboratories, Inc. This device is a next generation sequencing based in vitro diagnostic device for detection of single nucleotide variants, insertions, deletions, and large rearrangement variants of the *BRCA1* and *BRCA2* genes. This test also determines the Genomic Instability Score (GIS), a measurement of Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-Scale State Transitions (LST), which is used to identify ovarian cancer patients with positive homologous recombination deficiency (HRD) status.

On November 30, 2017, the FDA approved FoundationOne CDx, by Foundation Medicine, Inc. This device is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens.

## VII. Important Reminder

The purpose of this Medical Policy is to provide a guide to coverage. This Medical Policy is not intended to dictate to providers how to practice medicine. Nothing in this Medical Policy is intended to discourage or prohibit providing other medical advice or treatment deemed appropriate by the treating physician.

Benefit determinations are subject to applicable member contract language. To the extent there are any conflicts between these guidelines and the contract language, the contract language will control.

This Medical Policy has been developed through consideration of the medical necessity criteria under Hawaii's Patients' Bill of Rights and Responsibilities Act (Hawaii Revised Statutes §432E-1.4), or for QUEST Integration members under Hawaii Administrative Rules (HAR 1700.1-42), generally accepted standards of medical practice and review of medical literature and government approval status. HMSA has determined that services not covered under this Medical Policy will not be medically necessary under Hawaii law in most cases. If a treating physician disagrees with HMSA's determination as to medical necessity in a given case, the physician may request that HMSA reconsider the application of the medical necessity criteria to the case at issue in light of any supporting documentation.

Genetic testing is covered for level 1 or 2A recommendations of the National Comprehensive Cancer Network (NCCN and in accordance with Hawaii's Patients' Bill of Rights and Responsibilities Act (Hawaii Revised Statutes §432E-1.4) or for QUEST members, the Hawaii Administrative Rules (HAR 1700.1-42).

## VIII. Evidence-based Scientific References

- Bacino, C. (2019). Genomic disorders: An overview. <https://www.uptodate.com/contents/genomic-disorders-an-overview>
- Baumli, J. M., Li, B. T., Velcheti, V., Govindan, R., Curioni-Fontecedro, A., Doms, C., Takahashi, T., Duda, A. W., Odegaard, J. I., Cruz-Guilloty, F., Jin, L., Zhang, Y., Anderson, A., & Skoulidis, F. (2021). Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. *Lung Cancer*. <https://doi.org/https://doi.org/10.1016/j.lungcan.2021.10.007>
- Casali, P. G., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J., Brodowicz, T., Broto, J. M., Buonadonna, A., De Alava, E., Dei Tos, A. P., Del Muro, X. G., Dileo, P., Eriksson, M., Fedenko, A., Ferraresi, V., . . . Blay, J. Y. (2018). Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*, 29(Suppl 4), iv267. <https://doi.org/10.1093/annonc/mdy320>
- Casali, P. G., Blay, J. Y., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Boye, K., Brodowicz, T., Buonadonna, A., De Alava, E., Dei Tos, A. P., Del Muro, X. G., Dufresne, A., Eriksson, M., Fedenko, A., . . . Stacchiotti, S. (2022). Gastrointestinal stromal tumours: ESMO&#x2013;EURACAN&#x2013;GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up<sup>&#x2606;</sup>. *Annals of Oncology*, 33(1), 20-33. <https://doi.org/10.1016/j.annonc.2021.09.005>
- Comandini, D., Damiani, A., & Pastorino, A. (2017). Synchronous GISTs associated with multiple sporadic tumors: a case report. *Drugs Context*, 6, 212307. <https://doi.org/10.7573/dic.212307>
- FDA. (2017). *FoundationOne CDx*. <https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pma&id=407172>
- FDA. (2019). *MyChoice HRD CDx*. <https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pma&id=440605>

- FDA. (2020a). Cobas® EZH2 Mutation Test.  
<https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pma&id=455336>
- FDA. (2020b). FDA approves pembrolizumab for adults and children with TMB-H solid tumors.  
<https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors>
- FDA. (2020c). Guardant360 CDx.  
<https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pma&id=454228>
- FDA. (2020d). Therascreen BRAF V600E RGQ PCR Kit.  
<https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pma&id=448074>
- FDA. (2021). ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA).  
<https://www.accessdata.fda.gov/scripts/cdrh/devicesatfda/index.cfm?db=pma&id=454588>
- Guardant. (2020). Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers.  
<https://www.globenewswire.com/news-release/2020/08/07/2075187/0/en/Guardant-Health-Guardant360-CDx-First-FDA-Approved-Liquid-Biopsy-for-Comprehensive-Tumor-Mutation-Profiling-Across-All-Solid-Cancers.html>
- Hayano, T., Matsui, H., Nakaoka, H., Ohtake, N., Hosomichi, K., Suzuki, K., & Inoue, I. (2016). Germline Variants of Prostate Cancer in Japanese Families. *PLoS One*, 11(10), e0164233.  
<https://doi.org/10.1371/journal.pone.0164233>
- Hulick, P. (2020). *Next-generation DNA sequencing (NGS): Principles and clinical applications*.  
<https://www.uptodate.com/contents/next-generation-dna-sequencing-ngs-principles-and-clinical-applications>
- Judson, I., Bulusu, R., Seddon, B., Dangoor, A., Wong, N., & Mudan, S. (2017). UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST). *Clin Sarcoma Res*, 7, 6. <https://doi.org/10.1186/s13569-017-0072-8>
- Kalia, S. S., Adelman, K., Bale, S. J., Chung, W. K., Eng, C., Evans, J. P., Herman, G. E., Hufnagel, S. B., Klein, T. E., Korf, B. R., McKelvey, K. D., Ormond, K. E., Richards, C. S., Vlangos, C. N., Watson, M., Martin, C. L., & Miller, D. T. (2016). Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics [ACMG Statement]. *Genetics In Medicine*, 19, 249. <https://doi.org/10.1038/gim.2016.190>
- Klempner, S. J., Fabrizio, D., Bane, S., Reinhart, M., Peoples, T., Ali, S. M., Sokol, E. S., Frampton, G., Schrock, A. B., Anhorn, R., & Reddy, P. (2020). Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. *Oncologist*, 25(1), e147-e159. <https://doi.org/10.1634/theoncologist.2019-0244>
- Konnick, E. Q., & Pritchard, C. C. (2016). Germline, hematopoietic, mosaic, and somatic variation: interplay between inherited and acquired genetic alterations in disease assessment. *Genome Med*, 8(1), 100. <https://doi.org/10.1186/s13073-016-0350-8>
- Konstantinopoulos, P. A., Norquist, B., Lacchetti, C., Armstrong, D., Grisham, R. N., Goodfellow, P. J., Kohn, E. C., Levine, D. A., Liu, J. F., Lu, K. H., Sparacio, D., & Annunziata, C. M. (2020). Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. *Journal of Clinical Oncology*, 38(11), 1222-1245. <https://doi.org/10.1200/jco.19.02960>
- Kowalik, A., Zalewski, K., Kopczynski, J., Siolek, M., Lech, M., Hincza, K., Kalisz, J., Chrapek, M., Zieba, S., Furmanczyk, J., Jedlinski, M., Chlopek, M., Misiek, M., & Gozdz, S. (2019). Somatic mutations in BRCA1&2 in 201 unselected ovarian carcinoma samples - single institution study. *Pol J Pathol*, 70(2), 115-126. <https://doi.org/10.5114/pjp.2019.82905>
- Legrand, F., Renneville, A., MacIntyre, E., Mastrilli, S., Ackermann, F., Cayuela, J. M., Rousselot, P., Schmidt-Tanguy, A., Fain, O., Michel, M., de Jaureguiberry, J. P., Hatron, P. Y., Cony-Makhoul,

- P., Lefranc, D., Sene, D., Cottin, V., Hamidou, M., Lidove, O., Baruchel, A., . . . Kahn, J. E. (2013). The Spectrum of FIP1L1-PDGFR-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases. *Medicine (Baltimore)*, 92(5), e1-e9.  
<https://doi.org/10.1097/MD.0b013e3182a71eba>
- Li, M. M., Datto, M., Duncavage, E. J., Kulkarni, S., Lindeman, N. I., Roy, S., Tsimberidou, A. M., Vnencak-Jones, C. L., Wolff, D. J., Younes, A., & Nikiforova, M. N. (2017). Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. *J Mol Diagn*, 19(1), 4-23.  
<https://doi.org/10.1016/j.jmoldx.2016.10.002>
- Liu, S., Yu, Q., Han, W., Qi, L., Zu, X., Zeng, F., Xie, Y., & Liu, J. (2014). Primary gastrointestinal stromal tumor of the prostate: A case report and literature review. *Oncol Lett*, 7(6), 1925-1929.  
<https://doi.org/10.3892/ol.2014.1968>
- Lowrance, W. T., Breau, R. H., Chou, R., Chapin, B. F., Crispino, T., Dreicer, R., Jarrard, D. F., Kibel, A. S., Morgan, T. M., Morgans, A. K., Oh, W. K., Resnick, M. J., Zietman, A. L., & Cookson, M. S. (2021). Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. *J Urol*, 205(1), 22-29.  
<https://doi.org/10.1097/ju.0000000000001376>
- Marabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., Jr., Italiano, A., Kao, S., Piha-Paul, S. A., Delord, J.-P., McWilliams, R. R., Fabrizio, D. A., Aurora-Garg, D., Xu, L., Jin, F., . . . Bang, Y.-J. (2020). Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. *The Lancet Oncology*, 21(10), 1353-1365.  
[https://doi.org/10.1016/S1470-2045\(20\)30445-9](https://doi.org/10.1016/S1470-2045(20)30445-9)
- Martincorena, I., & Campbell, P. J. (2015). Somatic mutation in cancer and normal cells. *Science*, 349(6255), 1483-1489. <https://doi.org/10.1126/science.aab4082>
- McCabe, C. D., Spyropoulos, D. D., Martin, D., & Moreno, C. S. (2008). Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer. *Cancer Res*, 68(6), 1988-1996.  
<https://doi.org/10.1158/0008-5472.Can-07-5843>
- Merino, D. M., McShane, L. M., Fabrizio, D., Funari, V., Chen, S. J., White, J. R., Wenz, P., Baden, J., Barrett, J. C., Chaudhary, R., Chen, L., Chen, W. S., Cheng, J. H., Cyanam, D., Dickey, J. S., Gupta, V., Hellmann, M., Helman, E., Li, Y., . . . Allen, J. (2020). Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. *J Immunother Cancer*, 8(1). <https://doi.org/10.1136/jitc-2019-000147>
- Miller, D. T., Lee, K., Chung, W. K., Gordon, A. S., Herman, G. E., Klein, T. E., Stewart, D. R., Amendola, L. M., Adelman, K., Bale, S. J., Gollob, M. H., Harrison, S. M., Hershberger, R. E., McKelvey, K., Richards, C. S., Vlangos, C. N., Watson, M. S., & Martin, C. L. (2021). ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genetics In Medicine*, 23(8), 1381-1390. <https://doi.org/10.1038/s41436-021-01172-3>
- Miller, R. E., Leary, A., Scott, C. L., Serra, V., Lord, C. J., Bowtell, D., Chang, D. K., Garsed, D. W., Jonkers, J., Ledermann, J. A., Nik-Zainal, S., Ray-Coquard, I., Shah, S. P., Matias-Guiu, X., Swisher, E. M., & Yates, L. R. (2020). ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. *Annals of Oncology*, 31(12), 1606-1622. <https://doi.org/10.1016/j.annonc.2020.08.2102>

- Morgan, J., Raut, C., Duensing, A., & Keedy, V. (2021). *Clinical presentation, diagnosis, and prognosis of gastrointestinal stromal tumors*. <https://www.uptodate.com/contents/clinical-presentation-diagnosis-and-prognosis-of-gastrointestinal-stromal-tumors>
- Mottet, N., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Cumberbatch, M. G., De Santis, M., Fanti, S., Fossati, N., Gandaglia, G., Gillessen, S., Grivas, N., Grummet, J., Henry, A. M., van der Kwast, T. H., Lam, T. B., Lardas, M., Liew, M., Mason, M. D., Moris, L., . . . Cornford, P. (2021). EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. *Eur Urol*, 79(2), 243-262. <https://doi.org/10.1016/j.eururo.2020.09.042>
- Myriad\_Genetics. (2020). What is Myriad myChoice® CDx? <https://myriad.com/products-services/precision-medicine/mychoice-cdx/>
- Nagahashi, M., Shimada, Y., Ichikawa, H., Kameyama, H., Takabe, K., Okuda, S., & Wakai, T. (2019). Next generation sequencing-based gene panel tests for the management of solid tumors. *Cancer Sci*, 110(1), 6-15. <https://doi.org/10.1111/cas.13837>
- NCCN. (2018). *NCCN Clinical Practice Guidelines in Oncology*. [https://www.nccn.org/professionals/physician\\_gls/](https://www.nccn.org/professionals/physician_gls/)
- NCCN. (2021). NCCN Guidelines® & Clinical Resources. [https://www.nccn.org/professionals/physician\\_gls/](https://www.nccn.org/professionals/physician_gls/)
- NCCN. (2022). NCCN Guidelines® & Clinical Resources. [https://www.nccn.org/professionals/physician\\_gls/](https://www.nccn.org/professionals/physician_gls/)
- NCI. (2021). tumor mutational burden. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/tumor-mutational-burden>
- Pillar\_Biosciences. (2020). Clinical and Analytical Validation of the CE IVD ONCO/Reveal™ Dx Lung and Colon Cancer Assay [https://pillar-biosciences.com/wp-content/uploads/2021/04/AMP\\_2020\\_Pillar\\_Biosciences\\_16NOV20\\_v1\\_LC103v4\\_Nick.pdf](https://pillar-biosciences.com/wp-content/uploads/2021/04/AMP_2020_Pillar_Biosciences_16NOV20_v1_LC103v4_Nick.pdf)
- Pillar\_Biosciences. (2021). Assay User Manual ONCO/Reveal™ Dx Lung and Colon Cancer Assay. [https://pillar-biosciences.com/wp-content/uploads/2021/04/20210409-CE-IVD-assay-User-Guide-UM-0044-ONCO\\_Reveal-Dx-Lung-and-Colon-Cancer-Assay-User-Manual-CE-8435-1-8436-3.pdf](https://pillar-biosciences.com/wp-content/uploads/2021/04/20210409-CE-IVD-assay-User-Guide-UM-0044-ONCO_Reveal-Dx-Lung-and-Colon-Cancer-Assay-User-Manual-CE-8435-1-8436-3.pdf)
- Poduri, A., Evrony, G. D., Cai, X., & Walsh, C. A. (2013). Somatic Mutation, Genomic Variation, and Neurological Disease. *Science*, 341(6141), 1237758. <https://doi.org/10.1126/science.1237758>
- Pujol, P., Barberis, M., Beer, P., Friedman, E., Piulats, J. M., Capoluongo, E. D., Garcia Foncillas, J., Ray-Coquard, I., Penault-Llorca, F., Foulkes, W. D., Turnbull, C., Hanson, H., Narod, S., Arun, B. K., Aapro, M. S., Mandel, J.-L., Normanno, N., Lambrechts, D., Vergote, I., . . . Alés Martínez, J. E. (2021). Clinical practice guidelines for <em>B</em><em>RCA1 and BRCA2</em> genetic testing. *European Journal of Cancer*, 146, 30-47. <https://doi.org/10.1016/j.ejca.2020.12.023>
- QIAGEN. (2020). theascreen BRAF V600E RGQ PCR Kit. <https://www.qiagen.com/us/products/diagnostics-and-clinical-research/oncology/therascreen-solid-tumor/therascreen-braf-v600e-rgq-pcr-kit/>
- Raby, B., Blank, Robert. (2020). *Genetics: Glossary of terms*. <https://www.uptodate.com/contents/genetics-glossary-of-terms>
- Raby, B., Kohlmann, W., & Venne, V. (2020). Genetic testing. <https://www.uptodate.com/contents/genetic-testing>
- Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., Voelkerding, K., & Rehm, H. L. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*, 17(5), 405-424. <https://doi.org/10.1038/gim.2015.30>



- Robson, M. E., Bradbury, A. R., Arun, B., Domchek, S. M., Ford, J. M., Hampel, H. L., Lipkin, S. M., Syngal, S., Wollins, D. S., & Lindor, N. M. (2015). American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. *J Clin Oncol*, 33(31), 3660-3667. <https://doi.org/10.1200/jco.2015.63.0996>
- Takeda, M., Takahama, T., Sakai, K., Shimizu, S., Watanabe, S., Kawakami, H., Tanaka, K., Sato, C., Hayashi, H., Nonagase, Y., Yonesaka, K., Takegawa, N., Okuno, T., Yoshida, T., Fumita, S., Suzuki, S., Haratani, K., Saigoh, K., Ito, A., . . . Nishio, K. (2021). Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors. *The Oncologist*, 26(4), e588-e596. <https://doi.org/https://doi.org/10.1002/onco.13639>
- Terada, T. (2012). Small cell neuroendocrine carcinoma of the prostate: incidence and a report of four cases with an examination of KIT and PDGFRA. *Prostate*, 72(10), 1150-1156. <https://doi.org/10.1002/pros.22464>
- Thirunavukarasu, D., Cheng, L. Y., Song, P., Chen, S. X., Borad, M. J., Kwong, L., James, P., Turner, D. J., & Zhang, D. Y. (2021). Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection. *Genome Biology*, 22(1), 227. <https://doi.org/10.1186/s13059-021-02449-1>
- Woodhouse, R., Li, M., Hughes, J., Delfosse, D., Skoletsky, J., Ma, P., Meng, W., Dewal, N., Milbury, C., Clark, T., Donahue, A., Stover, D., Kennedy, M., Dacpano-Komansky, J., Burns, C., Vietz, C., Alexander, B., Hegde, P., & Dennis, L. (2020). Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. *PLOS ONE*, 15(9), e0237802. <https://doi.org/10.1371/journal.pone.0237802>

## IX. Policy History

Policy approved by Medical Directors	9/20/2022
Policy approved at UMC	12/16/2022
Policy effective	6/1/2023
Updated Lines of Business in the header	12/18/2023